Home
Live Updates
Optimized HF Meds May Lessen MR Severity, Avoid Invasive Therapy : comparemela.com
Optimized HF Meds May Lessen MR Severity, Avoid Invasive Therapy
Patients with heart failure and mitral regurgitation should get at least 6 months of optimized guideline-directed medical therapy before invasive mitral repair is considered, researchers say.
Related Keywords
Germany ,
United States ,
North Carolina ,
Massachusetts ,
Washington ,
Boston ,
Duke University ,
Berlin ,
America ,
American ,
German ,
Windtree Therapuetics ,
Jamesl Januzzi ,
Bristol Myers Squibb ,
Bristol Myers ,
G Michael Felker ,
Amgen ,
American Heart Association ,
Boehringer Ingelheim ,
Novartis ,
Pfizer ,
Astrazeneca ,
Novartis Pharmaceuticals ,
Cardiovascular Research ,
Blood Institute ,
National Heart ,
Harvard Medical School ,
German Center ,
Imbria Pharmaceuticals ,
Siemens ,
Medtronic ,
Trustee Of The American College Cardiology ,
Massachusetts General Hospital ,
Medscape Cardiology ,
Kansas City Cardiomyopathy Questionnaire ,
Heart Failure Society ,
America Annual Scientific Meeting ,
American College ,
Applied Therapeutics ,
Roche Diagnostics ,
American Regent ,
Cardiac Dimension ,
Failure Society ,
Breaking Clinical Trials Session ,
Mitral Regurgitation ,
Heart Failure ,
Reduced Ejection ,
Presented October ,
Cardiovascular Imaging ,
Ardiac Imaging ,
V Imaging ,
Echocardiography ,
Echocardiogram ,
Echo ,
Valve Repair ,
Renin Angiotensin System ,
Renin Angiotensin Aldosterone System ,
As Renin Angiotensin System ,
Aas Renin Angiotensin Aldosterone System ,
Clinical Research ,
Clinical Trials ,
Linical Studies ,
Healthcare And Medical Technology ,
Ealth And Medical Tech ,
Health A ,
comparemela.com © 2020. All Rights Reserved.